In 1974, Gospodarowicz described the presence of a potent mitogen for mouse 3T3 fibroblasts in extracts of brain and pituitary (5) . This activity was named fibroblast growth factor (FGF) and was subsequently purified from each of these bovine tissues (6, 7) . Both were characterized as basic molecules of-13,000 Mr that were acid and heat labile and as having common biological activities for a variety of cultured cells derived from embryonic mesoderm (9, 12) . It was suggested that they might be either related or identical (12) until it was shown that brain FGF could be separated into three forms, (FGF-1, 2, and 3) (7, 24) , corresponding to different peptide fragments of myelin basic protein (MBP), a structural protein of the central nervous system. Because brain and pituitary FGF preparations had different amino acid compositions and antigenic properties (preparations of brain, but not pituitary, FGF caused autoimmune experimental encephalitis in guinea pigs presumably because of the presence of the MBP fragments (24)), it was concluded that they were distinct entities.
Subsequently Thomas et al. (22) reported that, by three different criteria, the fragments of MBP did not possess the brain FGF activity. First, preparations of fragments produced from native bovine MBP, nearly identical to those reported to contain the brain FGF activity, were not mitogenic for BALB/ c 3T3 cells (22) or human dermal fibroblasts (1) , Secondly, the mitogenic activity in brain FGF preparations could be separated from the MBP fragments on an affinity column of insolubilized anti-MBP. Finally, the biological activity appeared to be associated with an acidic molecule, pI 5-6, as determined by isoelectric focusing.
Since brain FGF was found not to be associated with the MBP fragments, it again raised the possibility that the two mitogens could be the same, i.e. pituitary FGF might also be acidic, contrary to its reported properties (6) . In this report, we confirm the basic character of pituitary FGF. We also show that brain FGF contains at least two different mitogens, one acidic and one basic, the latter of which has properties similar to and hence may be identical with pituitary FGF. In agreement with our previous report (22) , neither the basic nor the acidic component of brain FGF corresponds to fragments of MBP.
MATERIALS AND METHODS

Anti-MBP Affinity Column
A chicken anti-bovine MBP affinity column was prepared and application and elution of samples were performed as described previously (22) . Briefly, bovine brain FGF samples were applied in phosphate buffered saline (PBS) (2) at room temperature to a 1.0-ml column and allowed to bind for about 10 rain. The column was washed with PBS until absorption at A280 and A~2o was negligible and was then further washed with 1 M NaCI in PBS and 2 M guanidine-HCl. Aliquots from the three protein pools were taken for bioassay, diluted with 2.0 mg/ml bovine serum albumin (BSA) (#4378, Sigma Chemical Co., St. Louis, MO) in PBS, and dialyzed against PBS. The remainder of each sample was dialyzed with 1 mM acetic acid and lyophilized for application to gels.
5DS and Acid Polyacrylamide Gel Electrophoresis
15% SDS polyacrylamide gels were prepared and developed according to the method of Laemmli (14) . Silver staining was performed as described previously (21) . Acid-gel-disc electrophoresis was performed by the type 'G' modified Reisfeld method as described by Rodbard and Chrambach (20) . 10%, 7.5 cm, polyacrylamide resolving gels and 3.0% stacking gels were polymerized with light in the presence of riboflavin-Y-phosphate. Samples were dissolved in 10% glycerol and a 1:10 dilution of upper running buffer. Gels were electrophoresed at approximately 4°C and 10 mamp for 2 h. This was the amount of time it took for a cytochrome c marker, which ran near the buffer front, to migrate close to the bottom of the gel. Sample lanes to be tested for bioactivity were cut into 0.25-cm segments and eluted by shaking overnight at 4°C in 1.0 ml of PBS and 2 mg/ml BSA. The remainder of the gel was stained with Coomassie Blue R 250.
Isoelectric Focusing in Polyacrylamide Slab Gels
Isoelectric focusing slab gels, pH 3-10, 7.5% acrylamide, and 10-cm long were prepared as follows: 7.5 ml of 30% acrylamide:0.8% bisacrylamide, 7.5 ml of 50% glycerol, 0.75 ml each of Pharmalytes pH 3-10 and pH 6.5-9 (Pharmacia Fine Chemicals, Uppsala, Sweden), and 12.5 ml H20 were combined and degassed. Polymerization was initiated by the additions of 1.0 ml of 1% ammonium persulfate and 7 ~1 of N,N,N',N'-tetramethylenediamine (TEMED). Focusing was performed on an LKB 2117 multiphor electrofocusing apparatus with cooling at 4°C and cathode and anode electrodes of 1 N NaOH and I N H:~PO4, respectively. Small wells were punched in the gel ~ 1.5 cm from the anode and samples were loaded in 10-30 p.1 dHeO. Cytochrome c markers were applied at 1.5 cm from both the cathode and anode. A constant power of 15 watts was applied until the voltage reached 1000 (-30 rain), after which the run was continued at a constant voltage of 1000 until the two cytochrome c markers met and the wattage and amperage had stabilized, ~l~Z~-2 h total electrofocusing time. Gel lanes to be tested for biological activity were cut into 0.5-em segments and eluted as described for acid gel samples. Gels were stained by the method of Reisner et al. (19) .
BALB/c 3T3 Cell Bioassay
The assay of mitogenic activity for BALB/c 3T3 fibroblasts was performed by measuring incorporation of [methyl-:~H]-thymidine into cells grown at 37°C in a humidified 5% CO~ atmosphere. Ceils were plated onto Costar 12 well-dishes (4 cm 2) at 8,000 ceils/well in 1.0 ml of medium (designated DME) which consisted of Dulbecco's modified Eagle's medium (high glucose) (DM 326 with 3.7 g/l of sodium bicarbonate added, KC Biologicals, Inc., Lenexa, KS) containing 100 units penicillin. 0.1 mg of streptomycin (Gibco Laboratories, Grand Island Biological Co., Grand Island, NY), and 0. l mg of glutamine (DME). This was supplemented with 10% calf serum (CS) (KC Biologicals, Inc.). -17 h later, the ceils were washed two times with DME without serum and then 1.0 ml of the same medium containing 0.4% caIf serum was added to wells. Cells were allowed to become quiescent for 30-54 h, after which samples to be tested were introduced in an additional 100 ~tl or less of DME containing 2 mg/ml BSA along with 1.12 ttg of dexamethasone in 20/tl of 50% ethanol. 16 h later, 2 gCi of [methyl-:~H] -thymidine (~70 Ci/mmoL ICN Pharmaceuticals, Inc., Irvine, CA) and 3/~g of unlabeled thymidine in 50 #l of DME were added. After a further 25 h, the assay was harvested. The ceils were washed three times with 1.0 ml 2.0 mg/ml BSA in HBSS and then precipitated with 1.0 ml of 5% TCA for 30 min on ice. After two more rinses with cold 5% TCA, precipitable material was solubilized with 1.0 ml of 2% Na~CO3 in 0.1 N NaOH for 1 h. A sample of 0.5 mI of the incorporated label was neutralized with 70/~1 of 50% TCA and 10.0-ml scintillation cocktail (3a70, Research Products International Corp., Mt. Prospect, IL) was added for counting. Results were obtained from triplicate determinations and standard deviations were generally < 10% of reported values.
Human Umbilical Vein Endothelial Cell Growth
Assays
Human umbilical vein endothelial (HUVE) cells were maintained as previously described (16) . For biological assay, cells between passage 3 and 11 were seeded into 35-mm culture dishes coated with 10 #g human fibroneetin/cm 2 at a density of 1 x 104 cells/dish in medium 199 and 20% fetal bovine serum (FBS) (Gibco Laboratories). Endothelial-cell growth factor (ECGF) (an extract as prepared in (15)) or FGF samples were added at this time, and cell cultures were fed every 2-3 d with the appropriate supplements. The assay was terminated after 10 d. The ceils were harvested by treatment with 0.05% trypsin-0.02% EDTA (Gibco Laboratories), trypsin was inactivated by the addition of soybean trypsin inhibitor (Sigma Chemical Co.) and duplicate hemocytometer counts obtained. Results are reported directly as the number of viable endothelial cells per dish.
Preparation of Pituitary FGF
Bovine pituitary FGF was prepared by the method of Oospodarowicz (6, 7) with minor modifications. Frozen pituitaries (Pel-Freeze Biologicals, Rogers, AR, or, the generous gift of Dr. D. A. K. Roncari, University of Toronto, Toronto, Canada) were homogenized in 0.15 M (NH4)2SO4 in the presence of 2.5 mg/1 leupeptin, 2.5 mg/1 pepstatin (Sigma Chemical Co.), 0.25 mM phenyl methyl sulfonyl fluoride (PMSF), and 1 mM EDTA. Acid extraction, subsequent ammonium sulfate precipitation, dialysis, and carboxymethyl-Sephadex (CM-Sephadex) 050 stepwise elutions were performed as previously described (6, 7) with the inclusion of 0.25 mM PMSF and 1 mM EDTA in all solutions. The Sephadex G-75 gel filtration column (2.5 x 90 cm), was run with 10-40 #m bed resin in 0.1 M ammonium bicarbonate. The active G-75 pool was loaded to the final CMSephadex C-50 column in 0.1 M sodium phosphate, pH 6.0, containing 0.1 M NaCI. The column was washed extensively with 0.1 M NaCI and 0.15 M NaCI in the phosphate buffer, followed by a gradient from 0.15 to 0.6 M NaCI in the same buffer. The final active fractions were pooled, dialyzed versus H~O and stored lyophilized at -20°C for <6 mo. Final amounts of protein were estimated by amino acid analysis on a Durrum D-500 amino acid analyzer (Dionex Corp., Sunnyvale, CA).
Preparations of Brain FGF
FGF from bovine brain was isolated by the method of Gospodarowicz et al (7, 24) with the following modifications.In one purification from 11 kg of tissue (Prep A), the active pool from the CM-Sephadex C-50 column was dialyzed overnight against 0.1 M ammonium bicarbonate, pH 8.5, in tubing with a Mr = 3,500 cutoff. This pool (1,400 ml) was then concentrated at 4°C by pressure filtration over a 4-d period using a PM 10 membrane to 50 ml, followed by further concentration in a smaller diameter UM I 0 membrane to 30 ml. This step replaced the more rapid lyophilization normally used. This material was loaded directly onto the Sephadex G-75 column and the active fraction purified through the last CM-cellulose step. The pooled FGF fractions (Prep A) were stored in 30 mM ammonium formate, pH 6.0, at -20°C for 2-3 yr.
In a second purification (Prep B), initial homogenization, extraction, and ammonium sulfate precipitation of 16 kg of brains were performed in the laboratory at room temperature, utilizing ice-cold buffers and refrigerated (4°C) centrifugation. All subsequent steps were done entirely in the cold. The following modifications were made to accelerate the first chromatography step. The active material from the second ammonium sulfate precipitation was dialyzed against water, Iyophilized, and dissolved in 500 ml of 0.1 M sodium phosphate, pH 6.0. This was mixed with 40 g of CM-Sephadex resin, equilibrated in the same buffer, stirred for 15 min, poured into a sintered glass filter and the excess liquid drawn out. The resin was mixed with starting buffer, poured into an 8.0-cm diameter column, and rinsed and eluted at 10 ml/min as previously described (7). The biological activity was eluted with 0.6 M NaC1 in the phosphate buffer, dialyzed overnight versus distilled water and lyophilized. This sample was dissolved in 0.1 M ammonium bicarbonate, pH 8.5 and applied and eluted from the Sephadex G-75 column as usual. The pooled active fractions from this chromatography were lyophilized directly and stored at -20°C for ~1.5 yr.
Protein concentration was estimated on the basis of an E2so of 0.79 for a 1 mg/ ml solution for(Prep A) and by weight for (Prep B).
fl-A, lercaptoethanol Treatment of Brain and Pituitary FGF
Pituitary (1/zg) and brain FGFs Prep A (5 #g) and Prep B (125 #g), in 0.08 M Tris-HCl, pH 8.5 were incubated for 30 min at 37°C in the presence or absence of 0. I-0.2% ,8-mercaptoethanol. The pituitary and brain Prep A FGF samples were diluted to 0.5 ml with 2.0 mg/ml BSA in PBS and dialyzed overnight at 4°C in tubing with a 3,500 mol wt cut off (18-mm diameter) against PBS before they were added to the 3T3-ceU bioassay. The brain Prep B FGF samples were dialyzed against several changes of distilled H~O over an 8-10 h-period, lyophilized, resuspended in distilled H20, and aliquoted for bioassay and isoelectric focusing.
RESULTS
Isoelectric Focusing of Brain and Pituitary FGF
In initial studies to compare the properties of the two brain FGFs and pituitary FGF, appropriate preparations were analyzed by isoelectric focusing. Pituitary (10 #g), brain Prep A (25 #g), and Prep B (90 #g) FGF were focused in 7.5% polyacrylamide slab gels, pH range 3-10, after which slices were cut, eluted, and tested for stimulation of incorporation of [methyl-:3H]-thymidine into BALB/c 3T3 cells. profiles of FGF activity. The 7.5% polyacrylamide gels with ampholytes of pH 3-10 were focused for 11/2-2 h as described in the text. Gels were sliced into 0.5-cm slices and eluted in 1.0 ml PBS, 2.0 rag/ ml BSA for bioassay. Results 2 are expressed as percent of maximal stimulation for each 0 FGF, which was determined by analysis of the dose-response 8 ~ curves of an aliquot from the 6 ,i loaded FGF-sample tested in the BALB/c 3T3-cell assay. gel with a pl of 8-9, confirming earlier reports of the basic nature of this mitogenic activity (6) . Unexpectedly, the older preparation of brain FGF (Prep A) (Fig. 1 B) showed a similar broad activity-peak in this region of the focusing profile, with possibly a very small amount of activity (<5%) at a pl of ~6.0. This was in apparent contrast to our previous results in which we found all of the brain FGF activity was associated with an acidic molecule (22) . However, when a second preparation of brain FGF (Prep B) was analyzed by isoelectric focusing (Fig.  1 C) , two active components were detected, a basic mitogenic activity with a pI similar to that in brain Prep A and pituitary FGF, and a more prominent species that focused with a pI of about 6.0 in this system. Myelin basic protein fragments, which were identified by staining of the gels, appeared to separate from the activities and migrated to the cathode, pI _>10.0. In control experiments, in which blank lanes with no applied protein were sliced, eluted, and tested in the 3T3-cell bioassay, no activity was seen ( Fig. 1 A, open triangles) .
Anti-MBP Affinity Column Chromatography of Brain FGF
In view of the fact that the Prep A of brain FGF contained primarily a basic mitogenic activity, we reexamined this material after passage through an anti-MBP affinity column (22) . 300 /~g of brain Prep A FGF were loaded in PBS and the column was washed sequentially with PBS, 1 M NaCI, and 2 M guanidine-HCl. As reported previously (22) , almost all of the biological activity recovered, as determined in the BALB/ c 3T3 assay, was not retained by the column and came through in the breakthrough PBS pool (87%) even though this sample consisted largely of a basic mitogen. 11% was found in the NaCI pool and <2% was contained in the guanidine-HC1 fraction, which included the MBP fragments, the bulk of the protein loaded on the column (data not shown).
The introduction of the highly sensitive silver-staining method for SDS polyacrylamide gels made it possible to identify the components in all of the fractions eluted from the anti-MBP column (Fig. 2) . ~ 1-2 #g of protein, estimated by absorption at A2~o, were analyzed from each fraction. As can be seen, the PBS pool (lane 1) contained three major staining bands that did not comigrate with any of the MBP fragments eluted by 2 M guanidine-HC1 (lane 3). The material eluted by 1 M NaCI (lane 2) contained some components found in both the guanidine-HC1 and PBS pools. Thus, the biological activity did not adhere to the anti-MBP affinity column and was not associated with fragments of MBP, confirming our previous report (22) .
Acid Gel Electrophoresis of Brain and Pituitary FGF
Preparations of pituitary, brain Prep A FGF, containing primarily a basic mitogenic component, and brain Prep B FGF, with two separable mitogenic activities, one acidic and one basic, were further examined by acid gel electrophoresis. 10 #g of pituitary and 10-20 #g of brain Prep A FGF were electrophoresed on 10% potyacrylamide acid pH gels, slices cut, and samples eluted for the 3T3-cell assay. As seen in Fig.  3 , pituitary (panel A) and brain Prep A FGF (panel B) had a single mitogenic activity that migrated to the same apparent position in the gel, very close to the chicken egg-white lysozyme marker. Although the brain FGF preparation used in this experiment had been partially purified by passage through the anti-MBP affinity resin, unfractionated samples of brain Prep A FGF gave identical activity profiles in the acid gels. 
Bottom
ToO FUGURE 3 Activity profiles of acid gel electrophoresis of FGF. Samples applied to 10% polyacrylamide type 'G' acid gels (19) were electrophoresed as described in the text. Gels were sliced into 0.25-cm fragments and eluted as in Fig. 1 for the 3T3-cell bioassay. Results are expressed as described in Fig. 1 In contrast, when brain Prep B FGF (90 #g) was analyzed by acid gel eleetrophoresis, two separate mitogenic entities were seen (Fig. 3 C) . There was a smaller peak of activity (20-30%) that migrated to the same position as pituitary and brain Prep A FGF and a slower migrating component (70-80%) that had a mobility in this system similar to chymotrypsinogen. This distribution of the two active components correlated well with the results of the isoelectric focusing gels. The MBP fragments migrated approximately between the two peaks.
In addition, it was found that virtually 100% recovery of activity of material loaded on the acid gels was obtained when slices were eluted into buffer containing carrier BSA. 10 #1 from samples eluted from sliced-blank lanes run without applied protein showed no stimulation of [methyl-3H]-thymidine into 3T3 cells.
Effects of FGF on HUVE cells
F G F preparations were tested for their ability to stimulate the growth of HUVE cells (Fig. 5) . In most experiments, pituitary FGF showed no activity, although occasionally, as shown in Fig. 5 B, a small amount was detectable when 100 ng/ml or greater were added. By comparison, this material showed half-maximal stimulation of activity in the BALB/c 3T3 cell assay at a dose of 0. !-0.5 ng/ml. Brain Prep A FGF, which produced a half-maximal response in the 3T3 cell bioassay at 5-10 ng/ml, displayed activity in the HUVE cell assay, but even at 250 ng/ml, it had not reached 50% of the ECGF level. In contrast, brain Prep B FGF was equipotent in both assays with half-maximal stimulation between 15 and 30 ng/ ml. In addition, it was as active in the HUVE cell assay at 4 ng/ml as brain Prep A FGF was at 250 ng/ml, a 60-fold difference.
Stability Studies
These brain and pituitary FGF preparations were also analyzed for their stability when subjected to reducing conditions. Samples were treated with or without /3-mercaptoethanol at 37°C, pH 8.5, for 30 min and then dialyzed to remove reducing agents. As shown in Table I , pituitary and brain Prep A FGF were not sensitive to these reducing conditions, as there was no significant difference in activities in the presence or absence of fl-mercaptoethanol when tested in the BALB/c 3T3 bioassay. In contrast, preparation B of brain FGF was markedly stabilized by fl-mercaptoethanol when subjected to pH 8.5 and 37°C and then dialyzed. In this experiment, there was a 40-50% reduction in biological activity in the absence of the thiol reagent, as compared with samples treated in its presence.
This stabilizing effect of ~-mercaptoethanol was further analyzed by isoelectric focusing of brain Prep B FGF samples that had been incubated with or without this agent. BrainPrep B FGF, 125 #g, was treated with or without 0.1-0.2% /~-mercaptoethanol for 30 rain at 37°C, pH 8.5. After extensive dialysis with distilled H20, samples were lyophilized, resuspended in H20 and focused in 7.5% polyacrylamide gels as described in the text. Gel slices, 0.5 cm, were eluted and 10 #1 from each was tested for biological activity in the 3T3 cell assay. Results are expressed as in Fig. 1. (A) shows that in the absence of reductant (panel B) the acidic component of this brain FGF was nearly undetectable; however, protection from inactivation was provided by the sulfhydryl compound (panel A), although there was still some decrease in the acidic constituent. In contrast, there was no loss of activity of the basic component of brain Prep B FGF with or without reductant, revealing another similar property of this activity to the FGF of pituitary and the Prep A of brain. Samples prepared without growth factors but in the presence offl-mercaptoethanol were inactive when tested for biological activity.
DISCUSSION
The present studies have reexamined the relationship of brain and pituitary FGF. Our experiments have confirmed that pituitary FGF is indeed basic as originally described (6) . All of the biological activity focused in the basic region of the isoelectric focusing slab gels and experiments on focusing columns in sucrose density-gradients with cruder preparations of pituitary FGF also showed that the major mitogenic activity is basic (data not shown).
When we compared pituitary FGF to two different preparations of brain FGF by isoelectric focusing, we found that the brain samples gave markedly different activity-profiles. One preparation (Prep A) contained primarily a basic mitogen that was similar to pituitary FGF in that it migrated to the same position in the acid pH gels and was insensitive to sulfhydryl reagents at 37°C. It was also shown not to be related to the MBP fragments. This was established in both electrophoresis systems utilized in these studies and by the alTmity chromatography and its subsequent analysis in SDS gels. Other investigators are in agreement with this finding (1, 13) .
The unexpected result was that this preparation of brain FGF contained little of the factor with the acidic pl that we originally described (22) . However, analyses, by the same methods, of a second preparation (Prep B), clarified this apparent discrepancy. We found this sample contained both an acidic component with mitogenic activity, corresponding to the activity described in our earlier report (22) , and a basic constituent resembling pituitary and brain Prep A FGF.
Although both the acidic and basic components were stimulatory for BALB/c 3T3 fibroblasts, only preparations that contained the acidic factor showed significant activity in the HUVE-cell assay. The amount of activity for HUVE ceils was reflected in the quantity of the acidic component in a given sample; that is, pituitary FGF had virtually no activity, brain Prep A FGF had very small amounts of activity, and brain Prep B FGF 'was a highly potent mitogen for these cells. In addition, only in the case of brain Prep B FGF was the growthfactor preparation as active in the HUVE-cell assay as it was in the 3T3-cell assay. That the acidic factor contains the HUVE-cell activity, though, is only inferred as we have been unable to test samples derived from polyacrylamide gels directly in these cultures without unacceptable losses in cell survival.
It is possible that the two components in preparation B of brain FGF are related in some way. For example, one activity could be produced from the other constituent by a latent proteolytic event. However, the fact that only brain FGF with the acidic material is active for HUVE cells, which is stabilized by fl-mercaptoethanol, whereas the basic components from brain and pituitary FGF do not show these properties, suggests that the two mitogenic activities are distinguishable entities.
The fact that the acidic and basic mitogens are apparently distinct proteins suggests that the variable amounts of these constituents in different brain FGF preparations are probably due to other reasons. There were several differences in the purification and storage of the two brain FGF samples used in these studies. The most significant was that Prep B was only purified through the Sephadex G-75 column, whereas Prep A was purified through the final CM-52 ion exchange column. However, this cannot account for the virtual absence of the acidic component in the further purified brain FGF. First, all of the studies presented in our earlier paper (22) were performed with brain FGF purified on a column of CM-52 with gradient elution and only the acidic component was observed on isoelectric focusing. Second, both the acidic and basic mitogenic components were observed with isoelectric focusing and acid gel electrophoresis when brain Prep B FGF was further purified through a final CM-52 column (data not shown). However, it should be noted that the bound protein fraction was eluted in a single step because biological activity extended over the entire gradient profile in most of our prior purifications of brain FGF. In these experiments, the acid gel electrophoresis showed identical amounts of the two activities, 20-30% basic and 70-80% acidic, as had been seen with the G-75 purified material.
Aging of brain FGF preparations may account, in part, for the loss of one constituent relative to the other. We have noted that brain FGF is generally less stable than pituitary FGF and this could be due to the presence of the more labile acidic component in brain FGF preparations. However, the difference in age in the brain-FGF samples used in these studies is not so great as to suggest that this is the main factor in the differences in content of the acidic mitogen. Rather, it is more likely that during manipulation of the samples or at other steps in the purification of brain FGF, recoveries of the two mitogens are altered. Slight variations in pH and ionic strength of buffers, temperature, length of dialysis or concentration, pooling of column fractions, storage conditions, and the age of the animals from which the bovine brains were obtained could determine the final ratio of the acidic to basic components. For example, it is possible that the loss of the acidic constituent in Prep A brain-FGF could be accounted for by the prolonged concentration step at pH 8.5 prior to the Sephadex G-75 purification, since it has been shown that the acidic component is labile to treatment at this pH at 37°C. Alternatively, storage of samples in solution (Prep A) versus lyophilized (Prep B) could be a contributing factor. At the present time, it is not clear what factors lead to the variable amounts of the acidic and basic constituents of brain FGF.
We are not certain why we did not observe the basic component of brain FGF in our earlier studies (22) . This form was probably contained in the brain FGF we originally analyzed, but because of insensitivity of the biological assay and the isoelectric focusing methods utilized at that time, which was 20-fold less sensitive, it was not detected. However, we do not feel that loss of the basic constituent in the earlier experiments was due to dialysis of samples with 10 mM acetic acid, as has been suggested by Gospodarowicz and Mescher (I0). In the initial reports of the characterization of brain FGF, substantial biological activity (80%) was retained when samples were treated for 24 h with as great as 100 mM acetic acid (7) .
In view of the conflicting results that have been obtained from isoelectric focusing of brain-FGF preparations, this may not be an adequate method with which solely to analyze these growth factors, especially when identification depends upon a mitogenic bioassay. In particular, there are difficulties in interpreting the basic region of isoelectric focusing-profiles. It has been noted that basic ampholytes can stimulate fibroblasts to divide (4) . Also, alkaline pH can result in mitosis of 3T3 cells (25) . Although assaying a blank run without added protein is a useful control, there exists the possibility that some of the mitogenic activity in a test sample is due to ampholytes that may act differently when associated with proteins. In addition, we cannot eliminate the possibility that some artifactual mitogenic activity in focusing experiments was observed when larger sample volumes, 5-10 /zl, were assayed, as we have sometimes seen >100% recovery, and the ratio of acidic to basic material in brain (Prep B) FGF did not always correlate with the analysis of the same preparation in acid gels. Therefore, this latter method that does not have unusual buffers, appears to give a more reliable indication of the amounts of the two constituents found in brain FGF preparations.
The presence of two distinct mitogens in preparations of brain FGF may explain the conflicting results with human endothelial-cell growth in culture. While Gospodarowicz and colleagues (8) have shown that high concentrations of brain and pituitary FGF can promote the growth of normal humanendothelial cells, these results have been difficult to confirm independently (15, 16) . It is also possible that bovine pituitaries contain the acidic growth activity. In our studies on pituitary FGF, we have noted the presence of other components mitogenic for 3T3 ceils, especially as seen by gel filtration, and Maciag et al. (15) have shown that pituitary extracts contain significant levels of activity for HUVE cells. Because we have only studied normal human endothelial-ceU growth with these reagents, it is presently not possible to extend our findings to normal bovine-endothelial cells (1 l, 18, 23 ). However, it should be noted that pituitary FGF, prepared in our laboratory, is highly active for an established line of bovine vascular-endothelial cells (P. R. Kelley, Collaborative Research Inc., Waltham, MA, personal communication), an observation consistent with other laboratories (3, 11) .
In conclusion, we feel that the experiments presented here have helped to clarify the contradictory findings surrounding studies with bovine fibroblast growth factors. We have definitively shown that brain FGF activity is not associated with fragments of MBP, but that these preparations do contain a basic component with properties very similar to pituitary FGF. At present, they are indistinguishable. The acidic constituent of brain FGF, present in some preparations, resembles closely and may be related to endothelial-cell growth factor, pI 5.0-6.0, that has been characterized by Maciag et al. (15, t7) . If these biological assignments prove to be correct, it would be reasonable to refer to the basic mitogens of brain and pituitary as "fibroblast growth factor" and retain the designation "endothelial-cell growth factor" for the acidic component. 
